0001193125-26-134476
SEC filingSCYNEXIS filed a Form 8-K on March 31, 2026 disclosing its ADPKD asset acquisition, $40M PIPE financing, and corporate update via a furnished presentation.
SCYNEXIS’ acquisition of global rights to SCY-770 from Poxel positions the company to enter the large, underserved ADPKD market, where the only approved therapy generated ~$1.5B in 2024 U.S. sales despite significant safety limitations. SCY-770, a Phase 2-ready AMPK activator, has demonstrated robust preclinical efficacy in ADPKD models and a favorable safety profile across 8 prior clinical trials, with a potential accelerated approval path via the FDA-endorsed TKV surrogate endpoint. The concurrent $40M PIPE financing extends the company’s cash runway to mid-2029, providing sufficient capital to execute its near-term pipeline plans including initiation of the SCY-770 Phase 2 trial in Q4 2026, advancement of its SCY-247 antifungal candidate, and pursuit of non-dilutive funding for SCY-247. The company also retains upside from its existing GSK partnership for BREXAFEMME, which is eligible for up to $146M in sales milestones plus royalties.